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Abstract 
Background: Coronary stents are routinely placed in the treatment and prophylaxis of 
coronary artery disease (CAD). Current coronary stent designs are prone to developing 
blockages: in-stent thrombosis (IST) and in-stent re-stenosis (ISR). This is a systematic 
review of the design of current coronary stent models, their structural properties and 
their modes of application, with a focus on their associated risks of IST and ISR. The pri-
mary aim of this review is to identify the best stent design features for reducing the risk 
of IST and ISR. To review the three major types of stents used in clinical settings today, 
determining best and relevant clinical practice by exploring which types and features 
of offer improved patient outcomes regarding coronary angioplasty. This information 
can potentially be used to increase the success rate of coronary angioplasty and stent 
technology in the future taking into account costs and benefits.
Methods: Scientific databases were searched to find studies concerning stents. After 
the exclusion criteria were applied, 19 of the 3192 searched literature were included 
in this review. Studies investigating three major types of stent design were found: 
bare-metal stents (BMS), drug-eluting stents (DES) and bioresorbable stents (BRS). The 
number of participants varied between 14 and 1264. On average 77.4% were male, 
with a mean age of 64 years.
Results: From the findings of these studies, it is clear that DES are superior in reducing 
the risk of ISR when compared to BMS. Conflicting results do not clarify whether BRS 
are superior to DES at reducing IST occurrence, although studies into newer BRS tech-
nologies show reducing events of IST to 0, creating a promising future for BRS showing 
them to be non-inferior. Thinner stents were shown to reduce IST rates, due to better 
re-endothelialisation. Scaffold material has also been shown to play a role with cobalt 
alloy stents reducing the risk of IST. This study found that thinner stents that release 
drugs were better at preventing re-blockages. Some dissolvable stents might be bet-
ter at stopping blood clots blocking the arteries when compared to metal stents. The 
method and procedure of implanting the stent during coronary angioplasty influences 
success rate of these stents, meaning stent design is not the only significant factor to 
consider.
Conclusions: Positive developments in coronary angioplasty could be made by 
designing new stents that encompass all the most desirable properties of existing 
stent technology. Further work is needed to investigate the benefits of BRS in reducing 
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the risk of IST compared to DES, as well as to investigate the effects of different scaffold 
materials on IST and ISR outcomes.
Keywords: Coronary, Stent, Angioplasty, Percutaneous, Intervention, 
Revascularisation, Review
Background
In coronary artery disease (CAD), the coronary arteries are narrowed or blocked, 
impeding the supply of oxygen to the heart, resulting in damage to the heart muscle and 
its function. Approximately 125,000 people in the United Kingdom die each year due 
to CAD, and it is the leading cause of death globally [1]. Percutaneous coronary inter-
ventions (PCI) and coronary artery bypass grafts (CABG) are the main treatments for 
narrowed or blocked arteries due to CAD. CABG is a surgical procedure that entails 
a vein, usually grafted from the leg, at points above and below the level of occlusion, 
hence creating a ‘bypass’. However, this procedure is not as simple as it may sound, as 
differences in pressure values of stenosed arteries need to be considered [2]. PCI is an 
invasive procedure performed to widen blocked or narrowed coronary arteries, allowing 
increased blood flow, to resupply oxygen to the cardiac tissue [3]. Traditionally, PCI has 
been performed using balloon angioplasty alone. Balloon angioplasty is a technique in 
which a small balloon is delivered to the site of coronary artery occlusion. The balloon is 
then inflated, re-establishing blood flow. Early studies suggested that balloon angioplasty 
resulted in higher mortality rates compared to CABG; tissue lining the arterial wall (the 
endothelium), could become damaged, weakening the arterial wall and leading to re-
narrowing of the artery (restenosis) [4]. This increased the risk of major adverse events, 
such as myocardial infarction and stroke [5].
Bare‑metal stents (BMS)
In 1986, Sigwart and Puel made major advances in PCI with the development of coro-
nary bare-metal stents (BMS). BMS are cylindrical metal wire meshes that are expanded 
using balloon angioplasty and then remain in situ post-procedure. They are designed to 
keep the artery open after the initial balloon inflation [6]. BMS were developed to reduce 
the high frequency of restenosis after balloon angioplasty.
However, deploying a stent with a metal-based scaffold into an artery has since been 
found to be problematic in several ways. The interaction between bare-metal stent struts 
and endothelium can lead to endothelial damage, activation of the clotting cascade, 
platelet aggregation, and, potentially, formation of a blood clot (in-stent thrombosis or 
IST) [7]. Vascular smooth muscle cells (which provide structural integrity to the arte-
rial wall) may also become damaged upon stent expansion, leading to vascular smooth 
muscle cell proliferation and migration to the surface of the endothelium as part of a 
process known as ‘neointimal hyperplasia’. Neointimal hyperplasia may reduce arterial 
lumen size and is thus increases the risk of in-stent restenosis (ISR) [8]. Patients who 
receive a BMS will be prescribed dual anti-platelet therapy (DAPT) for up to 12 months 
post-procedure. The drugs are usually aspirin and a drug that inhibits the key receptor 
for platelet aggregation  (P2Y12); clopidogrel and prasugrel being the most common. This 
therapy is provided to help reduce the risk of in-stent thrombosis (IST) [9].
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Drug‑eluting stents (DES)
Drug-eluting stents (DES) were first introduced in 1999 by Eduardo Sousa, to combat 
the high ISR risk of BMS. DES are metal-based stents with a durable-polymer layer, 
which elutes a drug after deployment [10]. The first drug used in DES was sirolimus, 
also known as rapamycin. Sirolimus is an immunosuppressive compound that inhibits 
the actions of mTOR, a kinase that promotes cell growth and proliferation. This inhi-
bition is thought to reduce the proliferation of vascular smooth muscle cells, making 
it a suitable drug target to reduce ISR with metal stents [11]. Everolimus, zotarolimus, 
and umirolimus (biolimus) are all analogues of sirolimus which have been shown to 
reduce neointimal hyperplasia [12–14]. Paclitaxel, a well-known anti-cancer drug, 
has also been used in DES. It has been shown to inhibit vascular smooth muscle cell 
proliferation [15] and disturbs microtubule organisation, increasing the production 
of unstable microtubules, which reduces neointima formation, thereby reducing the 
incidence of ISR [16, 17]. Conflictingly, these drugs also inhibit the endothelial cover-
age of the stent struts (endothelialisation). This can lead to inflammation and platelet 
aggregation against the exposed stent struts, leading to IST formation (very late stent 
thrombosis) [18].
Bioresorbable stents (BRS)
Bioresorbable stents (BRS) (also referred to as ‘biodegradable’ stents) were developed 
to combat the very late IST caused primarily by the presence of the metal stent struts. 
BRS are formed from biodegradable-polymers that form a strong radial scaffold. The 
ability of the stent to ‘disappear’ within 12 months of deployment reduces the risk of 
exposed stent struts arising, as with DES. BRS were designed so that the lesion in the 
arterial wall (atherosclerotic plaque) will have healed by the time the stent struts have 
degraded.
Poly-l-lactide is a biodegradable polymer commonly used in BRS as it degrades 
into lactic acid and so is metabolised by the body [19]. The everolimus-eluting biore-
sorbable stent (ABSORB) was the first of the commercially available BRS. ABSORBs 
performed well compared with DES; however, they were associated with a higher inci-
dence of IST and myocardial infarction [20]. These increased risks appear to negate 
the potential long-term benefits of the BRS [20].
More recent developments in the area have produced the magnesium based BRS, 
DREAMS (drug-eluting absorbable metal scaffold) 2G (2nd generation) sirolimus-
eluting Magmaris™ by Biotronik. This BRS lowers the incidence of IST dramatically, 
countering the main drawback of other BRS on the market, creating new potential 
for BRS treatments in the future. This was proven via a 12-month follow-up study on 
patients with the BRS implanted and a 3-year follow-up study on the same patients, 
showing that this BRS remains unproblematic in the long term. The patients were 
all deemed low risk, so the BRS is considered safe for this group only. Higher risk 
patients may not produce the same results. Refer to Table 1 for patient information 
and Table  2 for IST rates [21, 22]. The polymer-based structure is weaker than its 
metal counterpart, and there is therefore an increased risk of recoiling by the arte-
rial wall, leading to ISR. Typically, the stent struts of BRS are wider and thicker than 
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traditional metal stents, which affects the rate of endothelialisation of the stent as well 
as deliverability (see Table  3). A larger stent also requires a larger catheter profile, 
which subsequently requires a more accomplished clinician to complete the interven-
tion successfully [23].
Coronary stent structure
As a foreword, it is important to consider developments in coronary imaging technology, 
including magnetic resonance angiography (MRA) and rotational X-ray angiography 
[41, 42]. This allows for more accurate coronary imaging, detection and identification of 
pathologies. This could be decisive when choosing between PCI or CABG for the treat-
ment of CAD.
Although there have been great advances in stent development, the basic structure 
remains the same. Results of recent studies highlight the importance of structure, design 
and material optimisation of stents [43, 44]. A metal, metal alloy or polymer scaffold is 
made up of struts and assembled into a particular pattern (cell design). These struts can 
vary in thickness and number, which are thought to be factors affecting re-endotheliali-
sation [18]. Each structural property presents a large variation with different physiologi-
cal issues [45]. The current solution is a compromise between stent function and high 
associated risks of ISR and IST. Vast improvements are still needed.
The current increased rates of ISR and IST in current stent designs need to be fur-
ther investigated to understand the factors affecting such complications. This review, 
Table 1 Literature search terms (in quotation marks) used in the Ovid program
The right column indicates the number of papers that each search term generated. Number 11 indicates a search command 
where a search term from 1 to 8 must be searched for with one of the search terms in number 10. The removal of duplicates 
was an automatic process performed by the Ovid tool
Search terms Number of papers
Stent type
1 “bare metal stent ti,ab” OR “BMS ti,ab” 23,059
2 “drug eluting stent ti,ab” OR “DES ti,ab” 1,232,392
3 “everolimus eluting stent ti,ab” OR “EES ti,ab” 13,972
4 “sirolimus eluting stent ti,ab” OR “SES ti,ab” 74,773
5 “zotarolimus ti,ab” OR “ZES ti,ab” 4866
6 “biolimus eluting stent ti,ab” OR “BES ti,ab” 11,993
7 “paclitaxel eluting stent ti,ab” OR “PES ti,ab” 34,967
8 “bioresorbable stent ti,ab” OR “bioresorbable scaffold ti,ab” OR “BRS ti,ab” 15,216
9 1 OR 2 OR 3 OR 4 OR 5 OR 5 OR 6 OR 7 OR 8 1,343,784
Stent structure
10 “structure ti,ab” OR “design ti,ab” OR “strut ti,ab” OR “strut spacing ti,ab” OR “strut 
thickness ti,ab” OR “open cell design ti,ab” OR "closed cell design ti,ab”
4,341,522
11 9 AND 10 17,375
12 “coronary ti,ab” 884,389
13 11 AND 12 3,191
Search limitations
14 Limited to English language 3124
15 Limited to human 2392
16 Limited to full text 356
17 Duplicates removed 269
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therefore, aims to investigate past and current stent design as well as the associated 
physiological consequences. This will be achieved by systematically searching databases 
to identify the relevant literature. This should help form a summary of favourable prop-
erties that need to be considered in order to design a stent that incorporates solutions to 
current issues whilst still being effective as a vascular scaffold in the treatment of CAD.
Results
Literature search and selection process
Figure  1 summarises the literature search and selection process undertaken. From 
the initial search, 3191 papers were identified. Once these had been limited to those 
written in the English language, 67 papers were excluded, with a further 732 papers 
excluded as they were not human studies. Thus, 2392 papers remained. Of these, only 
356 had full texts available through the Ovid program. Once duplicates had been 
Table 2 A summary of clinical outcomes
The table displays quantitative results from the included literature including the number of cases of in-stent thrombosis, 
in-stent restenosis, target-vessel revascularisation (TVR), as well as the anti-coagulation protocol used




TVR (%) Anti‑coagulation protocol
[24] BRS 60 1 0 1.7 Not given
[25] BRS – – – – Not given
[26] DES – 15 0 – Not given
[27] BRS 90 2 0 – Clopidogrel, prasugrel, ticagrelor
[28] PES – – – – Clopidogrel (75 mg) for 12 months
[29] BMS 32 – – – Clopidogrel (75 mg) for 12 months
PES 93 – – –
[30] PES 30 0 0 – Clopidogrel (75 mg) for 12 months
[31] BES 369 6 – – DAPT for 12 months
EES 1178 13 – –
[23] SES 1261 5 – 4.1 DAPT for 12 months
BES 1264 15 – 5.2
[32] BES 765 2 – 5.0 Prasugrel for 12 months
EES 765 5 – 4.7
BMS 761 5 – 10.4
[33] DES 958 4 9 – DAPT for 12 months
ZES 961 6 7 –
[34] EES 846 3 – 3.8 DAPT for 12 months
EES 838 5 – 3.6
[35] DES 82 – 82 – Not given
[36] SES 32 – – – Not given
[37] SES 250 – 17 7.2 Clopidogrel (75 mg) for 12 months
BMS 250 – 52 18.8
[38] BRS – – – – Not given
[39] BMS 222 1 – 9.5 Clopidogrel (75 mg)
PES 161 1 – 1.9
[40] SES 41 0 4 26.7 Clopidogrel (75 mg) for 6 months
PES 41 0 15 8.7
[21] BRS 184 0 – 5.2 DAPT for 6 months (minimum)
[22] BRS 1296 9 – 4 DAPT for 1 year (minimum)
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Table 3 The summary of data collected through the literature search: study design, stent type, drug 
eluted and the concentration (µg/mm2), scaffold material used, polymer used, stent strut thickness 
(µm), number of participants, gender (% male), and age (years) using means and standard deviations 
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BMS – Silicone-
carbide
– 60 761 75.0 63.0 ± 11.0
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(Not given) (Not 
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(Not given) 82 65.9 58.3 ± 11.0
[36] Cohort SES Sirolimus 
(not 
given)
(Not given) (Not 
given)
140 32 93.8 65.2 ± 8.2




PBMA 140 250 78.0 67.4 
(IQR = 59.0–
75.4)
BMS – (Not given) – 76 250 78.0 66.7 
(IQR = 59.9–
74.7)
[38] Cohort BRS Everolimus 
(1.0)
PLLA PLLA 157 56 71.0 60.0 ± 8.0




– 65 161 72.7 69.1 ± 12.7
BMS – Stainless 
steel
– 80 222 75.7 69.8 ± 11.5
[40] RCT SES Sirolimus 
(2.0)
(Not given) PE/PLA (Not given) 46 85.0 66.8 ± 9.5
PES Paclitaxel 
(0.25)














PLLA 150 184 63.0 65.5 ± 10.8
[22] RCT BRS Everolimus 
(not 
given)
PLLA PLLA 156 1296 72.0 63·1 ± 10·1
RCT randomised control trial, BRS bioresorbable stent, DES drug-eluting stent, PES paclitaxel-eluting stent, BMS bare-metal 
stent, BES biolimus-eluting stent, EES everolimus-eluting stent, ZES zotarolimus-eluting stent, SES sirolimus-eluting stent, 
HD  high dosage, LD low dosage, PLLA poly-l-lactic acid, PDLLA poly-d,l-lactic acid, PLA poly-lactic acid, SIBS styrene isoprene 
butadiene. PBMA poly-N-butyl methacrylate, PLGA poly(d,l-lactide-co-glycolide), PE polyester
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removed by the Ovid program (n = 87), 269 papers remained. Conference abstracts 
and inaccessible full texts were removed upon attempting to access full texts (n = 119). 
In total, 148 full texts were examined for eligibility and 130 were excluded based on 
the exclusion criteria. The quality of full texts examined was assessed, excluding 25 
papers due to low impact factors, leaving 18 papers. An additional 2 papers were 























Records identified through Medline 
and Embase search using specific 
search terms.
(n=3,191)


























Low Impact Factor (n=25)
Additional relevant papers from 
manual search
(n=2)
Fig. 1 The systematic review diagram, based on PRISMA guidelines, used in this study representing the 
number of papers (n) excluded during the search process. Duplicates (n = 89) were removed by the Ovid 
software. Duplicates (n = 3) were removed by the single reviewer upon examination of full texts. CABG 
coronary artery bypass graft
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Literature search results
Table 1 summarises the data collected from the included studies. Ten of the 20 studies 
were randomised control trials (RCT) [22, 23, 28, 29, 32–34, 37, 39, 40], five were cohort 
studies [25, 27, 31, 36, 38], two were retrospective autopsy studies [26, 35], and three were 
prospective, single-arm trials [22, 24, 30]. Four studies looked at BMS, with one compar-
ing two BMS with varying strut thickness [39], and three comparing the effects of BMS 
and DES on ISR rates [29, 32, 37]. Six studies investigated BRS [21, 22, 24, 25, 27, 38], and 
19 out of the 20 included studies investigated at least one drug-eluting stent. There were 
missing data for the scaffold and polymer types used for some studies as well as strut 
thickness. Eight studies included stents using stainless-steel scaffolds [23, 26, 28, 29, 31, 
32, 37, 39], with five using cobalt alloys [24, 31–33, 39], one using platinum–chromium 
alloys [34], two using silicone-carbide scaffolds [23, 32] and one using absorbable mag-
nesium mixed with rare earth metals [21]. Strut thickness varied between 60 µm [31, 32] 
and 157 µm [27]. The number of participants varied between the studies, with some stud-
ies having as few as 14 participants [25] and some as many as 1296 [22]. Figure 2 shows a 
scatter plot of the study sample sizes and strut thicknesses. Of these participants, on aver-
age 77.4% were male, with a mean age of 64 years.
Outcome measurements
Neointima thickness and strut coverage measurements
The included studies differed in how investigators measured neointima thickness within 
the stented area, although many used a combination of imaging modalities. Intravascular 
Ultrasound is an imaging modality that uses sound waves to generate images with a reso-
lution of ~ 100–200 µm that can be analysed to determine neointima thickness as well as 
strut coverage (re-endothelialisation) [46]. Intravascular ultrasound was used in five stud-
ies [23, 26, 29, 34, 38]. Intravascular optical coherence tomography is a high-resolution 
(~ 10–20 µm) and contrast-imaging modality. Optical coherence tomography uses infrared 
light to distinguish between tissues, such as endothelium and neointima, which makes it 
an appropriate tool to measure neointima thickness accurately. Optical coherence tomog-
raphy was used by seven studies investigating neointima hyperplasia or strut coverage [23, 
26, 27, 29, 31, 32, 38]. Optical frequency domain imaging is a form of optical coherence 
Fig. 2 A scatter plot showing the data for participant number and strut thickness (µm)
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tomography that provides a higher resolution image and was used in one study [30, 46]. In 
the two autopsy studies, histological staining was conducted on slices of the stented artery 
to determine the presence of neointima as well as percentage strut coverage [24, 35].
In‑stent restenosis
Of the 20 included studies, seven investigated ISR as an outcome, with seven using coronary 
angiographies as an outcome measure [25, 26, 29, 33, 34, 39, 40]. Coronary angiography is 
an imaging modality that uses X-rays and a radio-opaque substance that is intravenously 
administered to highlight the coronary arteries to determine any narrowing (restenosis) 
[47]. One study used a combination of coronary angiography, optical coherence tomog-
raphy and intravascular ultrasound to detect ISR [26]. An autopsy study used histological 
staining to measure the restenosis of stented arteries [24]. Table 2 summarises the quantita-
tive results of ISR, IST, target-vessel revascularisation (TVR) as well as the anticoagulation 
protocol used in each study. Target lesion revascularisation (TLR) was defined as any PCI/
CABG intervention due to restenosis in a stented artery and was used as a measure of ISR. 
Similarly, TVR was defined as CABG or repeated PCI performed in the same target vessel. 
As a point of interest, angiography relies on accurate segmentation of the desired structure 
for the imaging technique to be useful. Novel solutions based on a multiscale algorithm that 
automatically segments coronary arteries [48], or the use of locally connected filters [49], 
create potential for data of higher accuracy to be gleaned from angiographies.
In‑stent thrombosis
Thirteen studies investigated in-stent thrombosis as an outcome, five of which used optical 
coherence tomography [27, 29, 31, 32, 38], eight used coronary angiography [29, 31, 33, 34, 
36, 37, 40, 45], three used IVUS [29, 34, 38], one used optical frequency domain imaging 
[30] and one used digital imaging [35]. Four studies used a combination to determine IST 
as an outcome [29, 31, 34, 38]. The Academic Research Consortium’s definition of IST was 
used by five studies [33, 34, 36, 37, 45]. This consisted of an angiographic confirmation of 
IST, with the thrombus originating in the stent or 5 mm proximal or distal to the stent; 
associated with ischemic symptoms [50].
Quality assessment
Table 4 summarises the quality assessment conducted on the reported literature. Eighteen 
out of twenty included studies were in the first quintile of the impact factor score [51]. Bias 
was also assessed, with eight studies having no detectable bias in their methodology based 
on the highlighted domains. However, eight studies showed signs of selection bias [23, 24, 
30–32, 35, 40, 45], four had signs of detection bias [27, 29, 35, 38], and four had perfor-
mance bias [24, 33, 35, 40]. Three studies had more than one subject of bias based on their 
methodology [35, 38, 40].
Discussion
This was a systematic review of 20 randomised control trials, cohort studies, and sin-
gle-arm trials. This review investigated the association between coronary stent type and 
structure, and the risk of clinical complications, namely in-stent restenosis and in-stent 
thrombosis.
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In‑stent restenosis
A randomised control trial conducted in 2011 compared a BMS and a paclitaxel-
eluting stent (PES) to investigate the effects on clinical outcomes such as ISR risk. 
Patients were blindly randomised to receive either a stainless-steel BMS (n = 32) or 
a stainless-steel DES which eluted paclitaxel through a Styrene Isoprene Butadiene 
polymer matrix (n = 93). Baseline patient characteristics were similar between the 
two groups (75.9% male vs 74.2% male; median (interquartile range (IQR)): 68.6 years 
(58.4–71.9), 60.4 years (53.1–69.1), respectively) [32], which is representative of the 
population [52]. Cross-sectional percentage stenosis was measured using optical 
coherence tomography at a 13-month follow-up and found the BMS group to have 
a significantly higher rate of stenosis compared to the paclitaxel-eluting stent (PES) 
group (mean ± SD%) 57.0 ± 19.4 and 41.7 ± 20.6 (p = 0.0005). This difference may be 
due to paclitaxel inhibiting the neointimal hyperplasia of the vascular smooth muscle 
cell in the arterial wall. This study demonstrates the superiority of DES in reducing 
the rates of restenosis.
A larger randomised control trial confirmed these findings, comparing a thin-strut 
BMS to a sirolimus-eluting stent (SES) [39]. They concluded that SES reduced the risk 
of ISR, as the rate of restenosis was significantly higher in the BMS group (n = 250) 
compared to the SES group (n = 250), 25.5% vs 17% (p < 0.001), respectively. However, 
Table 4 A summary of quality assessment
The table displays the included searched literature, with the journal each paper is cited from as well the associated impact 
factor quintile (Q1 = First Quintile, Q2 = Second Quintile), from the Scimago Journal and Country Rank [22]. Bias domains 
were determined by examination of study design and methodology of each paper [24]




[24] Circulation: Cardiovascular Interventions Q1 Selection bias
[25] Circulation: Cardiovascular Interventions Q1 Detection bias
[26] Circulation Q1 Selection bias, performance 
bias, detection bias
[27] European Heart Journal Q1 Selection bias
[28] Circulation: Cardiovascular Interventions Q1 Detection bias
[29] Circulation Q1 Selection bias
[30] Circulation: Cardiovascular Interventions Q1 Selection bias
[31] Catheterization and Cardiovascular Interven-
tions
Q1 Selection bias
[23] Circulation: Cardiovascular Interventions Q1 –
[32] Circulation Q1 Performance bias
[33] Circulation Q1 –
[34] Circulation: Cardiovascular Interventions Q1 –
[35] European Heart Journal Q1 Selection bias, performance bias
[36] European Heart Journal Q1 Detection bias
[37] European Heart Journal Q1 –
[38] Journal of the American College of Cardiology Q1 –
[39] Journal of Interventional Cardiology Q2 Selection bias, performance bias
[40] European Heart Journal Q1 –
[21] Cardiovascular Revascularization Medicine Q2 –
[22] Journal of the American College of Cardiology Q1 –
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the lesions in the BMS group were more complex than those in the SES, which may 
have affected the restenosis rates, therefore future work should consider the complex-
ity of disease when randomising participants. Comparing these two RCTs, patient 
characteristics were similar between the two studies, making the results more com-
parable and increasing the reliability of the smaller study. One explanation behind 
these significant differences in ISR rates between BMS and DES is due to the effects of 
the eluted drugs. Paclitaxel and sirolimus inhibit the proliferation of vascular smooth 
muscle cells; in BMS, this inhibition is absent, meaning vascular smooth muscle pro-
liferation increases the arterial wall thickness, applying pressure to the metal scaffold, 
thus causing collapse and restenosis of the artery. As well as this, a vascular injury 
may be induced by the expansion of the stent scaffold leading to a cascade of neoin-
tima hyperplasia, resulting in restenosis [53–55]. This vascular injury is thought to 
be reduced significantly by the use of thinner struts, as they are thought to inflict 
less pressure on the arterial wall on expansion, subsequently reducing the risk of ISR 
[56–58].
It was noted that the BMS used in the larger trial had a thin strut (76 µm), which has 
been shown to affect restenosis rates. This factor may limit the comparability between 
the two studies as this was not stated in the smaller trial [52]. The material of the scaffold 
used in the stent has also been shown to play a role in restenosis, with one study finding 
that stainless-steel BMS had a higher rate of ISR compared to cobalt–chromium alloy 
BMS [40]. The trial used rates of target lesion revascularisation (TLR) as a measure of 
restenosis. The rates of TLR were 1.9% in the cobalt–chromium alloy group, compared 
with 8.6% in the stainless-steel group (p = 0.006). The underlying mechanism causing 
this significant difference between the two scaffolds remains unclear; however, the find-
ing of this significant difference suggests stent material could further investigated in the 
future development of safer and more effective stents.
This study did not have a randomised allocation design and, therefore, the choice of 
the stent was influenced by the operator’s judgement. There was a higher rate of hos-
pitalisation in the stainless-steel group, and it is possible that rates of TLR may have 
been increased in this group due to more frequent angiographies at hospital visits. 
The cobalt–chromium alloy stent is also thinner (65 µm) than the stainless-steel stent 
(80  µm). Although they are both relatively thin, previous research has suggested that 
thinner struts reduce the rate of ISR, meaning that the scaffold material may not be the 
only factor affecting the TLR rates [45]. Further work could compare two BMS with the 
same strut thickness, but with different scaffold materials, removing strut thickness as a 
confounding variable.
Neointima hyperplasia and strut coverage
Although it is evident that DES is superior in reducing the risk of ISR when compared 
to BMS, there are still some drawbacks. The neointima hyperplasia-inhibiting drugs, 
such as sirolimus and paclitaxel, also inhibit the process of re-endothelialisation [11, 
15]. This is the process of the stent struts becoming integrated within the endothe-
lium as endothelial cells grow around the individual struts. A retrospective autopsy 
study found that stents with thrombi present had significantly more uncovered struts 
compared to stents without thrombi [35]. This demonstrates the significant impact 
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that uncovered struts have on the risk of IST. In DES, the percentage of uncovered 
struts has been shown to be significantly higher when compared to BMS [32]. An 
RCT found that BMS has a higher rate of restenosis compared to SES. This study 
shows that the percentage of uncovered struts was significantly higher in the DES 
group when compared to BMS (mean ± SD %) (5.7 ± 7.0 vs 1.1 ± 2.5; p < 0.0001) [37]. 
The difference in the number of uncovered struts may be due to the strut thickness 
[45]. These findings suggest that SES is at a higher risk of IST, due to a greater num-
ber of uncovered struts, compared to BMS. In the present study, the SES strut was 
very thick (140 µm). Although the BMS strut thickness could not be found in the lit-
erature, it is thought that BMS struts are typically thinner due to the lack of polymer 
coating of the drug matrix. The two groups had similar baseline patient characteris-
tics, removing this as a potential confounding variable. This significant difference has 
been seen in biolimus-eluting stents (BES) as well as SES [59].
Conversely, several studies have found favourable strut coverage of DES in SES and 
PES in single-arm trials [29, 30, 32, 60]. One study investigating strut coverage in PES 
found that ~ 90% of the neointima response and thickening occurred within the first 
three months and was sufficient for favourable strut coverage, with most stent struts 
covered at three months [60]. They concluded that at nine months, the rate of neoin-
tima hyperplasia and strut coverage was minimally different when compared to the 
rate at three months.
Optical coherence tomography was used to measure the neointimal coverage of 
the struts. Although it has a high resolution, it is not able to accurately distinguish 
between fibrin and neointima, questioning the validity of the results. This could sug-
gest that the clinical implications of uncovered struts occur after nine months. This 
study did not have a control, and therefore this early strut coverage may also be seen 
in BMS [61]. Important structural properties of the stent, such as strut thickness, 
which could potentially influence the rate of strut coverage, were not given in the 
study.
Support for this study comes from another single-arm trial, with a larger sample 
size (n = 60), that investigated an SES with a cobalt–chromium alloy, with thin struts 
(80  µm) [30]. They used optical frequency domain imaging modality to measure 
strut coverage at one, two and three months and found a favourable strut coverage 
at three months. This study demonstrated a favourable strut coverage, suggesting a 
lower thrombotic risk, showing that the SES has a satisfactory safety profile at a one 
year follow-up [30, 35]. These two studies may not be comparable due to the differ-
ence in drug release kinetics seen between PES and SES [30]. Paclitaxel seems to be 
unaffected by different release kinetics, however sirolimus seems to be effective only 
with mid-term drug release. This difference may be a result of the drugs’ different 
cellular mechanisms. Paclitaxel targets the microtubule organisation of the vascular 
smooth muscle cell, whereas sirolimus targets the mTOR molecule [11, 15, 25]. The 
use of optical frequency domain imaging presents the same issues as optical coher-
ence tomography, as although the resolution is greater in optical frequency domain 
imaging, compared to optical coherence tomography, the same issue remains in dis-
tinguishing between neointima and fibrin. Similarly, there was no control or compari-
son to BMS, and it is therefore difficult to determine the superiority of strut coverage 
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of DES compared to BMS [61]. The conflicting results from these studies suggest that 
vascular smooth muscle cell inhibition is not the only factor affecting strut coverage; 
strut thickness may also influence this.
Strut thickness and apposition
One RCT compared a thin-strut SES (60  µm) with a thick-strut BES (140  µm) when 
investigating the rates of IST. While there were no significant differences in the two 
groups at a 12-month follow-up, the rate of definite stent thrombosis was significantly 
higher in the BES group compared to the SES group (n = 5 vs n = 15, respectively, 
p = 0.03) [45]. This outcome suggests that the thicker BES had a higher rate of uncov-
ered struts, which has been shown to be a factor in IST [35]. Thinner struts, therefore, 
are thought to have an endothelialisation property that is lost with thicker stent struts 
[56]. This study had a large sample size (n = 2525) which sufficiently powered the inves-
tigation of IST and had a blinded assessor during clinical end-point measures, removing 
potential reporting bias. A scatter plot showing a summary of study population sizes and 
strut thicknesses can be found in Fig. 2. Stents with thinner struts have also been associ-
ated with lower rates of neointima hyperplasia and therefore ISR, due to the reduction in 
vascular injury by the struts [39]. Neointima hyperplasia also plays a role in the apposi-
tion (adherence to the arterial wall) of the stent struts when implanted, which is another 
potential factor in IST [62].
Neointima hyperplasia has been shown to increase the rate of incomplete stent appo-
sition (ISA) [38]. If a stent strut is well opposed to the arterial wall in the target vessel, it 
is suitably in-contact with it. A cohort study of 32 patients investigated the rates of ISA 
in an SES with a strut thickness of 140  µm, using optical coherence tomography and 
intravascular ultrasound [38]. Optical coherence tomography image capture detected a 
higher incidence of ISA relative to intravascular ultrasound, demonstrating the superior-
ity of optical coherence tomography as an imaging modality. Thrombus was detected 
significantly more frequently in malapposed struts compared to well-apposed struts 
(20.6% vs 2.0%, respectively, p < 0.001). The primary mechanism for ISA is thought to be 
due to the inhibition of the neointima proliferation caused by the sirolimus. Although 
this significantly reduced the ISR rates, uncovered malapposed struts are thought to be 
the primary mechanism for ISA, being a key thrombogenic marker thought to increase 
the risk of late stent thrombosis (LST) [62]. An RCT generated similar findings when 
comparing a BMS and a PES within thick struts (140 µm) in 2011 [32]. Optical coherence 
tomography was used to identify uncovered and malapposed struts. PES had a greater 
number and larger distribution of uncovered and malapposed struts compared to BMS, 
which may increase the risk of thrombotic events. Delayed healing with PES, caused by 
the inhibition of the neointima proliferation, leading to uncovered struts, increases the 
thrombotic risk [35, 63]. A similar study, using intravascular ultrasound, corroborated 
these findings, indicating that LST was associated with incomplete stent apposition [64]. 
However, the very thick stent struts used in the PES may be the cause of the incomplete 
endothelialisation rather than the eluted paclitaxel, as several studies have suggested that 
with increased thickness comes an increased endothelialisation process time [39, 45].
Malapposition of stent struts can also lead to uneven drug distribution, which can 
result in varied drug concentrations in different areas of the arterial wall [24]. An autopsy 
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study identified uneven distribution as greater inter-strut distances, which increased the 
risk of restenosis in DES [24]. This was due to areas with little drug elution leading to 
neointima hyperplasia, causing ISR. Other areas, however, have a very strong concen-
tration leading to increased inhibition of neointimal hyperplasia, reducing the rate of 
endothelialisation of stent struts, and increasing the risk of IST. Further investigations 
are required to determine whether the eluted drug, strut thickness or a combination of 
factors is increasing the risk of IST.
Bioresorbable stents and in‑stent thrombosis
Advancements in stent design have led to trials investigating the use of bioresorbable 
stent (BRS) struts in an attempt to reduce the increased thrombotic risk associated 
with metal DES. Once the drug elution process is completed, the stent struts and pol-
ymer-drug reservoir are surplus to requirements [65]. A cohort study investigated the 
reabsorption process of the BRS struts using optical coherence tomography and intra-
vascular ultrasound. The study concluded that the strut coverage of a poly-l-lactic acid 
based everolimus-eluting stent (EES) was similar to that of metallic struts [26]. The study 
also detected that the stent struts had lost substantial mechanical integrity as well as 
radial force. However, between baseline and 12-month follow-up, there was no radial 
displacement of struts. This reduced mechanical integrity was unsurprising due to previ-
ously reported results of porcine models using the same stent. The molecular weight of 
the struts decreased by 40% at 6 months and 70% at 12 months [66]. This suggests that 
the concept of ISR is a time-limited process that may not affect BRS. This study did con-
clude that the polymer-based struts, using optical coherence tomography, did not differ 
from observations seen in metallic-based struts. This study did not use a control, and it 
is therefore difficult to conclude that the presumed increase in strut coverage observed 
was due to the bioresorbable properties of the stent. Support for this study came from 
an RCT that showed that stents with bioresorbable or biodegradable-polymers were 
non-inferior in clinical safety and efficacy when compared to stents with durable poly-
mers [27, 33, 37]. The two EES compared only differed in strut polymer; the bioresorb-
able polymer was poly (d,l-lactide-co-glycolide), the durable polymer was poly-N-butyl 
methacrylate. This meant that extraneous variables were limited, and the patient groups 
had no significant difference in baseline characteristics. Using a biodegradable poly-
mer reduces the risk for potential strut malapposition as well as IST. Durable polymers 
have been shown to delay vascular healing, leading to incomplete strut coverage as well 
as increased inflammation and thrombosis [67]. This study was however, only patient-
blind, and therefore the operators knew which patients received which stent, increasing 
the risk of selection bias.
Another cohort study compared the effects of bioresorbable polymer stents and 
durable polymer stents. A stainless-steel BES was compared with either an EES or a 
zotarolimus-eluting stent (ZES), made up of cobalt–chromium alloy with a durable 
polymer. The BES had a poly-lactic acid polymer strut [36]. The clinical end-point for 
this study was the rate of IST, with 369 patients assigned to the BES group and 1178 
to the EES/ZES group. The rates of IST at 5 years were low amongst the groups (1.6% 
vs 1.9%, respectively), showing no significant difference between the two (p = 0.75). 
There was also no difference in target-vessel revascularisation (TVR), suggesting that 
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the BES bioresorbable stent is safe compared to the EES and ZES stents for long-term 
rates of IST. Although stent assignment was not random, a propensity score matching 
was performed with a ratio of 1:3 to allow for potential confounders, and to minimise 
selection bias. The BES had a strut thickness of 112  µm compared to 81  µm of the 
EES/ZES, which might influence the findings and may potentially mean that, if strut 
thicknesses were similar, the BES rates of IST would be lower. The scaffold materials 
used are different between the stents and this may affect the rate of re-endotheliali-
sation of the struts, leading to differences in strut coverage and potential rates of IST 
[40]. Previous studies investigating BMS have concluded that thinner struts have a 
lower rate of IST due to a higher rate of endothelialisation [39, 40]. Further work is 
required to investigate the effects of strut thickness of BRS on endothelialisation rates 
as well as IST rates.
A phase III clinical trial, BIOSOLVE III, reviewed a magnesium based BRS, 
DREAMS (drug-eluting absorbable metal scaffold) 2G (2nd generation) sirolimus-
eluting Magmaris™ by Biotronik. This BRS is sirolimus eluting and uses a scaffold 
composed of absorbable magnesium mixed with rare earth metals. Polymer used is 
PLLA and strut thickness is 150 µm. This trial proved the success of the BRS in 184 
patients, showing no incidences of IST up to 3  years. This was detected via angio-
graphic follow-up procedures. Other clinical outcomes were similar to those already 
exhibited by commonly used DES. Comparing this with the IST rate of Abbott 
Absorb III (1.1% after 1 year) [68] shows that perhaps BRS technology should not be 
dismissed due to its history of high IST rates.
BIOSOLVE IV then took place, examining a much larger cohort of patients totaling 
1075. IST occurred in 5 patients, 0.5% of the trial population, measured over a period 
of 12 months after stent implantation. Still an improvement from Absorb. The follow-
up is set 5  years from this initial examination and is yet to take place, so it is hard 
to assess IST in the long term for this larger sample trial. One key factor that could 
explain this low IST rate when compared with its problematic predecessor, Absorb, 
is the electropolished struts. Although the strut thickness is similar, this electropol-
ishing gives the struts smooth and rounded edges, as opposed to the sharp edges of 
Absorb, reducing the chance of IST [69]. Another factor reducing thrombogenicity is 
magnesium as the scaffold material. Magnesium is more electronegative than other 
metals used in scaffolds [70]. This electronegativity influences the blood in a way that 
reduces the chance of thrombosis.
However, stent design is not the only factor to consider regarding the successfulness 
of these products, the implantation procedure also has great influence, as shown by 
the Absorb IV trial. This tested Abbott’s Absorb BVS, which prior was withdrawn from 
the market due to concerns of IST incidents in the long term. This was tested in a ran-
domised trial with better procedural technique and patient compatibility. This showed 
the previously underperforming BRS to have the same IST rate after 1  year (0.5%) as 
the Magmaris™ scaffold and widely used DES [71]. Anti-coagulation protocols should 
also be considered in reported IST rates as several studies used slight variations of dual 
anti-platelet therapy (DAPT). It could be suggested that the difference seen in IST rates 
between different stent structures and designs could be due to varied anticoagulation 
protocols. Table 2 lists the anti-coagulation protocols used within the studies.
Page 17 of 21Stevens et al. BioMed Eng OnLine           (2021) 20:46  
Conclusions
This review of stent usage in coronary angioplasty has found that drug-eluting stents 
(DES) are superior to bare-metal stents (BMS) with less risk of in-stent re-stenosis (ISR). 
Research reviewed here points to an uncertainty on which stent type is more superior 
in reducing in-stent thrombosis (IST), bioresorbable stents (BRS) or DES. Furthermore, 
strut thickness is believed to play a role in IST, with thinner struts reducing the risk. 
Re-endothelialisation rates are also thought to be affected by strut apposition, with 
malapposition leading to an increased risk of IST. The stent scaffold materials can also 
play a crucial role in inducing IST. Thus, cobalt alloy stents are superior to stainless-
steel stents. Further clinical outcome analysis reveals that DES with cobalt–chromium 
alloy are safer and more efficient than their associated counterparts. However, DES 
still have persisting issues with uncovered struts leading to IST. Therefore, future work 
should focus on resolving this issue through BRS. While BRS have been shown to be as 
effective as DES, it is still unclear whether they are superior in effectiveness or safety, 
despite promising early research. Lastly, as many of these studies report varying clinical 
end-points, other clinical outcomes, such as target-vessel revascularization (TVR) rates 
remain unanswered.
Based on the findings of this review, there is a continuing need for further develop-
ments in coronary angioplasty by designing stents with structural properties that have 
thus far been shown to be the most desirable, such as thinner struts and bioresorbable 
polymers. Further work is needed to clarify the benefits of BRS in reducing the risk of 
IST compared to DES, as well as to investigating the effects of different scaffold materials 
on IST and ISR.
Methods
Search strategy
A literature search was conducted using MEDLINE (1946 to February 2021) and 
EMBASE (1974 to February 2021) between October 2020 and February 2021 using the 
Ovid program. The Cochrane Review guidelines were used as a template for our search 
strategy. The search terms used focused on two main aspects: stent type (BMS, DES, 
BRS) and stent structure, such as strut thickness and cell design. (Table 1 contains a full 
list of the search terms used.) All literature contained at least one search term for each 
of the two main aspects in either the title or abstract (search restricted by the use of the 
Boolean operator: “ti,ab”).
Exclusion criteria
After the initial search, a number of criteria illustrated below were applied to exclude 
unrelated publications. They include:
• Duplicates
• Literature unrelated to search terms
• Conference abstracts
• Systematic reviews
• Inaccessible full texts
• Publication not in English
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• Non-human subject studies
• Unrelated to stent design
• Stenting of non-coronary arteries.
After exclusions had been applied, the literature bibliographies were examined for 
potential additional articles of relevance [10].
Assessment of bias
The quality of the included literature was assessed throughout the process of data col-
lection using Cochrane Review quality assessment guidelines, which advise assessing for 
selection bias, performance bias, detection bias, attrition bias, and reporting bias within 
the Methodology. Selection bias was determined by how the study allocated participants 
to groups, such as sequence generation and allocation concealment. Performance bias 
was based on how the two groups differed in the treatment or care received during the 
study, such as the blinding of participants and investigators. Detection bias was deter-
mined by the outcome measures and whether the assessors were blinded to the groups. 
Reporting bias was based on which results were reported and whether some results 
were excluded from the report due to the nature of the findings. This assessment was 
not included within the exclusion criteria, however potential biases were considered 
during the analysis of findings. The quality of the literature was also assessed based on 
the impact factor of the journal from which the paper was cited. The impact factor was 
deemed low if the journal presenting the literature had an impact factor lower than the 
second quintile of the Scimago Journal and Country Rank, which is based on the num-
ber of citations per paper per year (latest data from 2017) [28].
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